Table 3 Response rates for patients with cirrhosis
From: Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
Genotype | Treatment | Duration (weeks) | SVR (%) | Trials |
|---|---|---|---|---|
1 | Telaprevir + Peginterferon-alpha + Ribavirin | 12 + 12 or 12 + 36 | 75 | ADVANCE |
Harvoni | 12 | 98 | ION | |
Olysio + Sovaldi | 24 | 100 | COSMOS | |
Viekira Pak + Ribavirin | 24 | 95 | TURQOUISE | |
Sofosbuvir + Peginterferon + Ribavirin (Treatment-naïve) | 12 | 80 | NEUTRINO | |
2 | Peginterferon + Ribavirin (Treatment-naïve) | 24 | 62 | FISSION |
Sofosbuvir + Ribavirin (Treatment-naïve) | 12 | 83 | FISSION | |
Sofosbuvir + Ribavirin (Non-responders & Relapsers) | 12 | 60 | FUSION | |
16 | 78 | FUSION | ||
3 | Peginterferon + Ribavirin (Treatment-naïve) | 24 | 30 | FISSION |
Sofosbuvir + Ribavirin (Treatment-naïve) | 24 | 92 | FISSION | |
Sofosbuvir + Ribavirin (Non-responders & Relapsers) | 12 | 19 | FUSION | |
16 | 61 | FUSION |